Objective: To evaluate 3 Tesla (T) whole-body diffusion-weighted magnetic resonance imaging (WB DWI) for early treatment assessment in aggressive non-Hodgkin lymphoma (NHL). Methods: Fourteen patients with NHL treated with standard chemotherapy underwent 3-T WB DWI before and 2 and 4 weeks during treatment, using b-values of 01000 s/mm 2 from which the apparent diffusion coefficient (ADC) was calculated. Patient follow-up (average 20.3 months, range 1523 months) was the reference standard. Volume and ADC changes between baseline and 2 weeks (Vratio 2w , ADCratio 2w ) and 4 weeks (Vratio 4w , ADCratio 4w ) of responding and non-responding lesions (lymph node and organ lesions) were compared using MannWhitney U tests. The per patient values of Vratio N and ADCratio N to predict progression-free survival were determined with a log-rank test. Results: Eight patients showed complete remission and 6 showed tumour progression. The ADCratio 2w and ADCratio 4w differed significantly in lesions showing tumour progression versus complete remission (ADCratio 2w ¼ 4 AE 21% versus 119 AE 68%; ADCratio 4w ¼ 18 AE 61% versus 155 AE 78%; both P50.0001); the Vratio 2w and Vratio 4w did not (P40.05). Per body region, the ADCratio 2w showed a negative predictive value of 100% and positive predictive value of 86%. Per patient, the ADCratio 2w and ADCratio 4w correlated significantly with progression-free survival (P50.05). Conclusion: 3-T WB DWI with ADC quantification may enable early treatment assessment of aggressive NHL.
Introduction
Lymphomas are a heterogeneous group of malignancies arising from lymphoid tissue, with varied clinical and biological features classified according to morphologic, immunophenotypic and genetic features. The most common type of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphoma (DLBCL), which accounts for about 30% of lymphoid neoplasms [1] . T-cell lymphomas (TCL) represent about 12% of NHL. Aggressive or high-grade NHL is defined as a subgroup that shows severe clinical symptoms and rapid disease progression if untreated.
The prognosis and outcome for patients with aggressive NHL are influenced by accurate staging at diagnosis and correct and timely recognition of treatment response. [ 18 F]Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is being increasingly used instead of contrast-enhanced computed tomography (CT) for the staging and treatment follow-up of aggressive NHL and efforts have been made to standardize the performance and interpretation criteria of FDG-PET for staging and treatment assessment [2] . Compared with CT alone, FDG-PET/CT shows improved differentiation of post-treatment residual tumoural disease from post-treatment fibrosis. Although it was shown that interim PET during treatment effectively predicts the outcome for patients with DLBCL, the clinical value of early treatment evaluation with FDG-PET regarding patient management is not yet entirely clear [35] . Magnetic resonance imaging (MRI) is emerging as an efficient whole-body (WB) imaging modality combining sequences with adequate spatial and contrast resolution. However, using only conventional imaging sequences makes WB MRI, similar to CT, largely dependent on morphologic and size-related criteria for lesion characterization, potentially decreasing its value for nodal characterization or (early) treatment assessment [6] . Assessment of T2 signal intensity (SI) may be of additional use to differentiate post-treatment residual fibrotic masses and differentiate fibrotic tissue from masses at risk for relapse. However, previous studies suggest that optimal accuracy may only be reached 6 months after the end of treatment but clinically relevant decisions must be taken in the early stages of treatment [7, 8] . Several studies have indicated the additional value of functional MR techniques to conventional MRI for lesion characterization and early treatment assessment in various solid tumours [911] . Diffusion-weighted MRI (DWI) characterizes tissue by probing changes in random water molecule mobility related to differences in the tissue microstructure. These lead to changes in SI with increasing diffusion sensitization (b-value), which can be quantified by the apparent diffusion coefficient (ADC), allowing viable tumour to be differentiated from necrosis and inflammation irrespective of the underlying lesion morphology [12] . Recent and rapid technological developments have made the technique suitable for WB imaging in addition to morphologic imaging [1315] .
Recently, studies at 1.5 T investigated the feasibility of WB DWI for early treatment assessment of lymphoma [16] . Also, preliminary data indicate that DWI may be used as a response marker very early during treatment for lymphoma [17] . The aim of this pilot study was to evaluate WB DWI at 3 T performed at 2 and 4 weeks after the start of treatment for early assessment of treatment response in aggressive NHL.
Designs and methods

Patients
The study was approved by the local ethics committee and all patients gave written informed consent before the study. Patients with histological proof of NHL and scheduled for standard chemotherapy were included. Exclusion criteria were history of previous other malignancy or haematologic disorder, contraindications to MRI (such as pacemaker or claustrophobia) and pregnancy.
Fifteen consecutive patients who met these inclusion criteria with histopathologically proven NHL (13 de novo developed DLBCL and 2 TCL) were included in this prospective single-centre study between October 2008 and March 2009. One patient with DLBCL did not complete the treatment schedule due to treatmentinduced toxicity and was consequently excluded. The following details for the 14 remaining patients are shown in Table 1 : the lymphoma (sub)type, disease location, Ann Arbor staging and international prognostic index (IPI) score calculated from the patients age (460 years), Eastern Cooperative Oncology Group (ECOG) scale (patients performance ranging from asymptomatic to chronically bedridden), blood level of lactate dehydrogenase (LDH), number of extranodal disease sites and disease stage. Routine pretreatment evaluation and Ann Arbor staging were based on clinical examination, laboratory screening, PET/CT, lymph node excisional biopsy 1  DLBCL  GCB  II  Infradiaphragmatic  1  R-CHOP 14  2  DLBCL  ABC  IIE  Infradiaphragmatic  Stomach  3  R-CHOP 14  3  DLBCL  ABC  IV  Infradiaphragmatic  Skeletal  2  R-CHOP 14  4  DLBCL  GCB  IV  Infradiaphragmatic  Skeletal  3  R-CHOP 21  5  DLBCL  ABC  IV  Infra-supradiaphragmatic  Skeletal, uterine  4  R-CHOP 21  6  DLBCL  GCB  IIIE  Infra-supradiaphragmatic  Caecum  1  R-CHOP 14  7  DLBCL  GCB  III  Infra-supradiaphragmatic  3  R-CHOP 21  8  DLBCL  GCB  IV  Infra-supradiaphragmatic  Skeletal  5  R-CHOP 14  9  TCL  ALCL  I  Supradiaphragmatic  0  CHOP 21  10  DLBCL  GCB  II  Infradiaphragmatic  2  R-CHOP 21  11  DLBCL  ABC  IV  Supradiaphragmatic  Skeletal  2  R-CHOP and bone marrow biopsy. Clinical response assessment was based on PET/CT examinations after 3 cycles for study purposes, conforming to the protocol of ongoing clinical trials at our centre, and at the end of the chemotherapy schedule, according to international guidelines [2] . For DLBCL, the treatment schedule consisted of 68 cycles of R-CHOP (rituximab 375 mg/m 2 intravenous (iv) day 1; cyclophosphamide 750 mg/m 2 iv day 1; vincristine 1.4 mg/m 2 iv day 1; doxorubicin 50 mg/m 2 iv day 1; prednisone 100 mg by mouth days 15); 5 patients received a 2-weekly schedule of R-CHOP (R-CHOP 14 , R-CHOP plus addition of growth factor support, Pegfilgrastim (Neulasta Õ ) 6 mg subcutaneous injection, day 2) and 7 patients received a 3-weekly schedule (R-CHOP 21 ). The 2 patients with TCL were treated with CHOP, not including rituximab.
In addition to routine diagnostic procedures, 3-T WB DWI was performed before and 2 and 4 weeks after the initiation of treatment. All MRI studies were well supported by the patients and were of sufficient quality to allow analysis.
Imaging technique
WB MRI
WB imaging, covering the brain down to the proximal one-third of the upper legs, was performed on a 3-T MRI scanner (Achieva; Philips, Best, The Netherlands) with parallel radiofrequency transmission. The application of parallel radiofrequency transmission significantly improves image quality with respect to signal homogeneity and fat suppression [18] . Images were acquired using the built-in Q-body coil, which does not allow parallel imaging; however, the absence of surface coils maximizes patient comfort and minimizes patient positioning time.
Conventional WB MRI as anatomical reference for the WB DWI images and for measurement of lesion volume consisted of a coronal T2-weighted short tau inversion recovery (STIR) sequence acquired in 4 imaging stations. 2 ) from which ADC maps were automatically calculated. After acquisition, the transverse DW images were coronally reformatted using the built-in multiplanar reformatting (MPR) software and combined into a single stack of coronal WB DWI images with a slice thickness of 5 mm.
PET/CT
Patients fasted for 6 h before the PET/CT examination (Biograph 40 TruePoint with TrueV, Siemens Medical Solutions, Erlangen, Germany). Single-section WB spiral CT (40-slice Siemens Sensation, 85 mAs, 120 kV, slice thickness 5 mm, collimation 24 Â 1.2 mm, table feed 23 mm/rotation) was performed after intravenous injection of 120 ml of a contrast agent containing 300 mg iodine/ml. PET/CT images were acquired 60 min after intravenous administration of FDG at an average dose of 302.6 MBq (range 220388 MBq). PET was performed with an optimal in-plane resolution of 4.5 mm and an axial FoV of 216 mm. PET images were corrected for attenuation using the CT data.
Image analysis
Lesion identification and imaging correlation
Lymph node and organ lesions diagnosed as malignant by pretherapeutic clinical and imaging (PET/CT) assessment were included for evaluation by WB DWI and WB STIR.
In total, 138 lesions corresponding to 61 regions were delineated and analysed. Of the 138 lesions, 80 were lymphadenopathies (mean longest axis diameter 2.5 AE 2.3 cm, including 1 tonsillar lymphoma location (longest axis diameter 1.3 cm)), 3 lesions were at a visceral location (stomach, caecum and uterus, mean longest axis diameter 7.7 AE 1.2 cm) and 55 lesions were located in the bone marrow (mean longest axis diameter 2.7 AE 1.5 cm). At baseline, these target lesions were first identified and located on the coronal reformatted WB DWI acquired with b ¼ 1000 s/mm 2 (b1000 image) and WB STIR and correlated with FDG-positive lesions on the coronal PET/CT images. After lesion annotation on the coronal images, the lesions were automatically identified by the software on the corresponding co-registered transverse b0 and b1000 images. Lesions were also topographically annotated by their slice position and anatomical position. These target lesions for longitudinal follow-up were identified on WB DWI and WB STIR at 2 and 4 weeks follow-up by visual correlation and correlation of slice positions with the baseline examination.
WB STIR
Volumetric analysis was performed on the WB STIR images by 2 readers in consensus (KDP and RO). On these T2-weighted images, the signal of background tissue (fat, muscle, bone) is suppressed and lymph node and organ lesions are depicted as hyperintense structures. For each lesion, contours were drawn around the lesion border at each slice position and lesion volume was 
WB DWI
After correct lesion localization, the WB DWI images were quantitatively interpreted by 2 readers in consensus (CB and VV), blinded from clinical and other imaging data. For quantitative assessment, a similar approach was used as described in the literature [19] . Regions of interest (ROIs) were placed over lymphoma localizations on the b0 images and automatically copied to the other b-value images by the software. For solid nodal and extranodal lesions, the ROIs were placed over the entire lesion. In the case of obvious solid and necrotic components on the DW images, ROIs were placed on the solid tumoural components according to their signal heterogeneity on the b1000 images [19] . Native high b-value images allow the separate tissue components to be identified. Currently, there is no agreement as to which b-value best delineates intact tumoural tissue from necrosis or background tissue. Therefore, for this study, the native b1000 images were chosen to identify solid tumoural areas from background or necrosis as it is most likely that the suppression of T2 shine-through effects in necrosis or fluid-containing regions is most effective and that the volume of solid tumoural tissue cannot be overestimated due to remnant signal in necrotic areas.
For each lesion, all ROIs were combined into a single ROI and the average SI was then calculated for each b-value. These averaged SI values were then used to calculate the ADC (in mm 2 /s) using the following equation: ADC ¼ (À1/1000) Â ln(SI b1000 /SI b0 ) where SI b1000 and SI b0 are the SI measured on the b1000 and b0 images, respectively.
Subsequently, for early treatment follow-up at 2 and 4 weeks after the start of chemotherapy, the ADC changes (ADCratio N , in %) for each lesion between baseline and 2 and 4 weeks were calculated using the following formula: ADCratio N ¼ {(ADC N ÀADC B )/ADC B } Â 100 where ADC B represents the pretreatment ADC value and ADC N represents the ADC at either 2 or 4 weeks after the start of treatment.
PET/CT PET images were qualitatively evaluated. The standard uptake value (SUV) is not routinely used at our institution and was not applied for determination of PET results. Response assessment was performed according to the recommendations of the imaging subcommittee of the international harmonization project in lymphoma [2] . The extent and intensity of all foci of abnormal uptake were evaluated using a 3-point scale (1, low; 2, moderate; 3, high) within each lymphatic area, organ and skeletal region. Negative was defined as having no residual uptake or as having a single residual site of uptake with an intensity of 1. Positive was defined as having at least 1 residual site with an intensity score of at least 2 or the presence of at least 2 residual sites with any extent and intensity score.
Reference standard: treatment outcome
For clinical follow-up, patients underwent PET/CT after completion of treatment and were further followed by the treating physician at the outpatient clinic every 3 months during the time of study follow-up. Imaging studies, CT and/or PET/CT, were performed at the discretion of the treating physician when tumour progression or relapse was suspected. The total patient follow-up time was on average 20.3 months (range 1523 months). Progressionfree survival (PFS) was defined as the time between the end of therapy and the time of disease progression in case of tumour recurrence, or between the end of therapy and the end of follow-up in case of clinical remission (CR). CR was defined as the absence of all detectable clinical evidence of disease and disease-related symptoms, absent FDG uptake in nodal and extranodal residual masses, and absence of lymphoma infiltrations on repeat bone marrow biopsy (in case of bone marrow involvement before treatment). Tumour recurrence was defined as any new or persistent lesions of more than 1.5 cm in any axis on follow-up CT and/or any persisting or new lesions with pathologic focal FDG uptake not attributable to inflammation, confirmed by biopsy and histopathology.
Statistical analysis
Statistical analysis was done using Analyse-it 2.12 (Analyse-it Software, Ltd., Leeds, United Kingdom) and SPSS 11.0 for Windows (SPSS, Chicago, IL, US) A P-value50.05 was considered statistically significant. The ADCratio N and Vratio N of nodal and extranodal lymphoma locations showing CR versus recurrence during follow-up were compared with the MannWhitney U test. If a statistical difference was found, a further receiver operating curve (ROC) analysis with area under the curve (AUC) was used to investigate the discriminatory capability of the ADCratio N and Vratio N . After determining the optimal cut-off (giving equal weight to sensitivity and specificity), the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of the imaging parameters were determined per body region taking into account the lesions with lowest ratio N in each body region. For each of these values, the 95% binomial confidence interval (CI) was also provided.
On a per patient base, survival analysis was performed towards the PFS using the KaplanMeier product-limited (actuarial) method. The ADC ratio was dichotomized using the same threshold as for the per body region analysis, taking into account the lesion with the lowest ADC ratio per patient. The statistical significance of differences between curves was compared with the log-rank test for the imaging parameters and IPI score.
Results
Treatment outcome
Eight of the 14 patients (57%) showed CR at the end of follow-up. Three patients (21%) showed persisting or progressive disease at the end of standard treatment. Treatment intensification, which consisted of radiotherapy of the persisting disease site, was possible in only 1 patient (7%), leading to CR in this patient. In the other 2 patients (14%), rapid disease progression was noted followed by death. Three patients showed tumour recurrence during the follow-up period. Histologically proven tumour relapse occurred in the brain in 1 patient at 8 months after treatment, not related to previous affected sites; in nodal stations and spine in 1 patient at 12 months after treatment, related to previously affected sites; and in nodal stations in 1 patient at 6 months, also related to previously affected sites. All 3 patients received salvage treatment consisting of R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin) and/or radiotherapy. One of these 3 patients died during the follow-up period, 1 patient went into CR and 1 patient was alive under palliative care.
WB STIR
Lesion-based analysis
Per lesion, Vratio 2w and Vratio 4w showed no significant difference between lesions showing persisting or recurrent disease compared with lesions with CR (Vratio 2w ¼ À51 AE 32% versus À71 AE 34%; Vratio 4w ¼ À56 AE 46% versus À83 AE 32%; both P40.05). Due to lack of statistical significance, further region-and patient-based analyses were not performed.
WB DWI
Lesion-based analysis
Per lesion, ADCratio 2w and ADCratio 4w were significantly different in lesions showing persisting or recurrent disease compared with lesions with CR. At 2 and 4 weeks during treatment, the ADC ratios compared with baseline were significantly lower in non-responding than in responding lesions (ADCratio 2w ¼ 4 AE 21% versus 119 AE 68%; ADCratio 4w ¼ 18 AE 61% versus 155 AE 78%; P50.0001) (Fig. 1) .
Region-based analysis
When we assigned the lesion with the lowest ADCratio 2w as representative of the respective region, a ROC analysis incorporating equal weighting to sensitivity and specificity calculated the optimal thresholds for ADCratio 2w and ADCratio 4w as 25% and 40%, respectively. Using these thresholds, the ADCratio 2w yielded a sensitivity for detection of CR of 100% (CI 74100%), specificity of 90% (CI 7099%), accuracy of 94% (CI 8099%), NPV of 100% (CI 82100%) and PPV of 86% (CI 5798%). The ADCratio 4w showed a sensitivity of 83% (CI 5298%), specificity of 91% (CI 7199%), accuracy of 88% (CI 7397%), NPV of 91% (CI 7199%) and PPV of 83% (CI 5298%) ( Table 2) .
Patient-based analysis
In the survival analysis, no significant differences in PFS could be found between the group with IPI score 41 compared with the group with IPI score 1 (P ¼ 0.6). However, patients for whom ADCratio 2w and ADCratio 4w of all lesions were above these thresholds did show statistically longer PFS (ADCratio 2w , P ¼ 0.0002; ADCratio 4w , P ¼ 0.005) (Fig. 2) . The ADCratio 2w correctly identified all 8 patients showing CR, and 5 of 6 patients with persisting disease or later recurrence as illustrated in Figs. 3 and 4 . The ADCratio 4w correctly identified 7 of 8 patients with CR as illustrated in Fig. 5 , and 5 of 6 patients with persisting disease or later recurrence, but misclassified 2 patients. 
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Clinical PET/CT PET/CT data were acquired at the time of diagnosis, after 3 cycles (PET 3cycles ) of chemotherapy and at the end of treatment (PET endtreatment ). PET 3cycles showed complete metabolic response in 7 of 8 patients with later CR and near-complete response with one residual hypermetabolic focus (intensity grade41) in 1 of these 8 patients. Of the 6 patients with primary refractory disease or relapse, the PET 3cycles showed at least 2 persistent lesions in 4 patients and complete metabolic remission in 2 patients.
PET endtreatment showed a complete metabolic response in 8 of 8 patients with CR at the end of follow-up. In the 6 patients with primary refractory disease or relapse, PET endtreatment showed persistent disease in 4 patients and complete metabolic remission in 2 patients.
Comparative data between the different DWI and FDG-PET time points are shown in Table 3 .
Discussion
This pilot study investigated the value of 3-T WB DWI using the built-in body coil for early assessment of treatment response to standard chemotherapy in aggressive 
Treatment response in non-Hodgkin lymphoma 59
NHL, correlated to a follow-up based reference standard. NHL localizations that responded well during patient follow-up showed a significantly higher ADCratio 2w and ADCratio 4w compared with non-responding lymphoma localizations. In contrast, changes in lesion volume failed to show significant differences between responding and non-responding lesions. It is known that a decrease in lesion size in response to cytotoxic agents often occurs in the delayed phase or may be absent due to the development of fibrosis making the differentiation between responders and non-responders difficult, especially in the early treatment phase. This potentially makes size-based imaging inefficient as an early marker for treatment response [20, 21] . Cellular and vascular changes in response to cytotoxic treatment are known to precede changes in lesion size or occur when size changes are lacking, making DWI a potential early indicator of tumour chemosensitivity towards cytotoxic treatment [22] . In previous studies on breast cancer, primary and metastatic liver cancer, skeletal sarcoma, brain tumours and head and neck cancer, a substantial increase in ADC has been consistently correlated with successful treatment [19, 2327] . These ADC changes may relate to the induction of necrosis and apoptosis in response to cytotoxic treatment [28] . For NHL, the possible inverse correlation between ADC changes and tissue microdensity during treatment follow-up has been investigated by Huang et al. [29] in NHL xenografts. Treated tumour xenografts exhibited an increased ADC and had much lower cell density and cell proliferation and higher levels of apoptosis in comparison with non-treated controls. This is in concordance with a previous study using an animal glioma model in which biologically relevant outcome measures, such as cell kill and animal survival, correlated significantly with early changes in cellular density and mitotic index [27] . Recently, 2 studies investigated the feasibility of 1.5-T WB DWI for early treatment assessment of lymphoma. Lin et al. [16] found a significant increase in ADC in residual persisting masses after treatment, thereby potentially reducing the number of false-positives caused by size analysis alone. WB DWI findings were correlated to short follow-up and findings on PET/CT. In a second study, Wu et al. [17] noted a significant increase in ADC as early as 1 week after the start of chemotherapy and after 2 cycles of chemotherapy, and the PET/CT measured tumour metabolic activity and volume decrease at the same time. No significant difference was found in the study of Lin et al. [16] between the ÁADC of PETpositive and PET-negative regions, which were considered attributable to the small percentage of positive PET scans, and short time of follow-up.
In addition to these previous studies, we found a significant correlation between ADCratio N , the eventual occurrence of tumour relapse and PFS during the 1523 months of follow-up. In a study monitoring chemoradiation of head and neck cancer, DWI 24 weeks after the start of chemoradiation allowed prediction of the clinical response after 2 years of follow-up [19] . Similarly, DWI 3 weeks after the start of chemoradiation correlated with pretreatment DWI has been shown to predict time to progression and overall survival in patients with glioma [27] . All imaging techniques misclassified 1 patient with stage IV DLBCL, who reached remission on all target lesions but developed a biopsy-proven tumour relapse in the brain parenchyma during follow-up. In contrast, ADCratio 2w correctly predicted tumour relapse in 1 patient with DLBCL who showed good response on FDG-PET after 3 cycles and at the end of treatment. However, these localizations showed lower FDG avidity on the pretreatment scan, possibly hampering adequate evaluation of treatment response. In a previous report, DLBCL glucose metabolism measured by SUV and ADC showed no correlation. Because SUV as a marker for tumour metabolism and ADC as a marker for tumour microstructure are different indices characterizing malignancy, both should be considered to provide complementary diagnostic information [30] . 
þ, predicted as TP, À, predicted as CR; FP, false-positive; FN, false-negative.
One of the potential difficulties with patient-based treatment assessment with WB DWI compared with assessment of a single lesion or organ system, as in head and neck cancers or brain tumours, is to correlate the early response of a multitude of separate tumoural localizations in a single patient to the eventual treatment outcome of that patient. In cytotoxic treatment of systemic disease such as NHL, a homogeneous response cannot be expected to occur in all lesions. This is illustrated in our patient population, where treatment failure was often based on insufficient response of a single or a few lesions even with the other localizations showing excellent treatment response. Therefore, the patientbased analysis was primarily based on the heterogeneity of response over all lesions, with the identification of the least responsive lesion being predictive for PFS. Simplified, analysis of patient outcome should aim at detection of lesions with the lowest ADC ratio during treatment, although this should still be confirmed in larger studies. This concept of heterogeneity of response also drives our choice for ROI delineation based on tumour heterogeneity, only including the b1000 hyperintense, or suspected solid, tumoural areas. Early treatment assessment should aim at timely selection of non-responders, in whom small surviving intratumoural deposits may be responsible for tumour relapse while large parts of the tumour become necrotic. If whole lesion delineation was performed, lack of ADC changes in small surviving tumoural parts may have been masked by excessive ADC changes in the neighbouring responding tissues [19] . Nevertheless, we acknowledge that this methodology combining qualitative and quantitative interpretation should preferably be validated in larger studies.
A current issue is the need for time-consuming manual ROI delineations to calculate ADC values. Moreover, the calculated mean or median ADC ratio may not entirely reflect the intratumoural changes in response to treatment [31] . More automated evaluation methods incorporating tumour heterogeneity on a voxel or subvoxel level, such as functional diffusion maps (fDM), may have the added value of reflecting the intralesional heterogeneity of treatment response, thereby possibly improving diagnostic accuracy [31] . However, to our knowledge the fDM has not yet been applied for evaluation of multiple lesions in WB DWI. In addition, similar to a recent study of Horger et al. [32] , we obtained reasonable accuracy by calculating changes in averaged ADC obtained from ROIs based on visual assessment of b1000 SI tumoural heterogeneity.
There were some limitations to this study. First, the number of patients was small, but the significant study findings provide a basis for more extensive studies integrating WB DWI in the early treatment assessment of aggressive NHL. Second, this study was performed on a 3-T system using the built-in body coil, which may limit the comparison or extrapolation of these results to other studies or systems with different field strength or coil set-up. Although the major disadvantage of using the built-in body coil is the inability to use parallel imaging to increase the signal to noise ratio and decrease artefacts, it enabled us to perform efficient WB imaging with maximal patient comfort and minimized time loss due to patient positioning. However, the availability of dedicated WB surface coil designs with large coverage in the z-axis is increasing and will likely become the standard method for WB imaging [33] . Nevertheless, our study shows the ability to perform WB imaging at 3 T with the built-in body coil may remain beneficial in case of patients with claustrophobia or high levels of discomfort or morbidity, e.g. in tumour-induced pain syndromes such as multifocal skeletal metastases.
Third, in this study no direct comparison of WB DWI and FDG-PET/CT at identical time points was performed. However, in the setting of this pilot study in a small patient group, we opted to minimize the additional burden to the patient by limiting the FDG-PET/CT scans to those required for routine clinical purposes in our centre. Nevertheless, we acknowledge that in further studies, scanning at similar and preferably early time points is advised to compare both imaging modalities and evaluate their potential synergistic value.
Conclusions
In this pilot study, WB DWI with the ADCratio 2w and ADCratio 4w allowed for early assessment of treatment response, correlating significantly with the PFS during an average 20 months of follow-up. Lower ADCratio 2w and ADCratio 4w values were indicative of worse treatment outcome. However, larger studies are required to further evaluate the potential role of WB DWI as an early biomarker in the treatment of aggressive NHL.
